Molecular basis for cooperative binding and synergy of ATP-site and allosteric EGFR inhibitors

Beyett, Tyler S.; To, Ciric; Heppner, David E.; Rana, Jaimin K.; Schmoker, Anna M.; Jang, Jaebong; De Clercq, Dries J. H.; Gomez, Gabriel; Scott, David A.; Gray, Nathanael S.; Jänne, Pasi A.; Eck, Michael J.

doi:10.1038/s41467-022-30258-y

Title: Molecular basis for cooperative binding and synergy of ATP-site and allosteric EGFR inhibitors

Journal Article · 08 May 2022 · Nature Communications

DOI: https://doi.org/10.1038/s41467-022-30258-y · OSTI ID:1866855

;

; Rana, Jaimin K.;

; Jang, Jaebong; De Clercq, Dries J. H.; Gomez, Gabriel;

;

Abstract Lung cancer is frequently caused by activating mutations in the epidermal growth factor receptor (EGFR). Allosteric EGFR inhibitors offer promise as the next generation of therapeutics, as they are unaffected by common ATP-site resistance mutations and synergize with the drug osimertinib. Here, we examine combinations of ATP-competitive and allosteric inhibitors to better understand the molecular basis for synergy. We identify a subset of irreversible EGFR inhibitors that display positive binding cooperativity and synergy with the allosteric inhibitor JBJ-04-125-02 in several EGFR variants. Structural analysis of these complexes reveals conformational changes occur mainly in the phosphate-binding loop (P-loop). Mutation of F723 in the P-loop reduces cooperative binding and synergy, supporting a mechanism in which F723-mediated contacts between the P-loop and the allosteric inhibitor are critical for synergy. These structural and mechanistic insights will aid in the identification and development of additional inhibitor combinations with potential clinical value.

View Journal Article

Cite

Export

Save

Sponsoring Organization:: USDOE

Grant/Contract Number:: AC02-06CH11357

OSTI ID:: 1866855

Journal Information:: Nature Communications, Journal Name: Nature Communications Journal Issue: 1 Vol. 13; ISSN 2041-1723

Publisher:: Nature Publishing GroupCopyright Statement

Country of Publication:: United Kingdom

Language:: English

References (46)

Lessons To Be Learned: The Molecular Basis of Kinase-Targeted Therapies and Drug Resistance in Non-Small Cell Lung Cancer Lategahn, Jonas; Keul, Marina; Rauh, Daniel Angewandte Chemie International Edition, Vol. 57, Issue 9 https://doi.org/10.1002/anie.201710398	journal	January 2018
Genomic landscape of acquired resistance to third‐generation EGFR tyrosine kinase inhibitors in EGFR T790M‐mutant non–small cell lung cancer Lee, Jiyun; Kim, Hong Sook; Lee, Boram Cancer, Vol. 126, Issue 11 https://doi.org/10.1002/cncr.32809	journal	March 2020
Conformational Preferences of π–π Stacking Between Ligand and Protein, Analysis Derived from Crystal Structure Data Geometric Preference of π–π Interaction Zhao, Yuan; Li, Jue; Gu, Hui Interdisciplinary Sciences: Computational Life Sciences, Vol. 7, Issue 3 https://doi.org/10.1007/s12539-015-0263-z	journal	September 2015
A Myristoyl/Phosphotyrosine Switch Regulates c-Abl Hantschel, Oliver; Nagar, Bhushan; Guettler, Sebastian Cell, Vol. 112, Issue 6 https://doi.org/10.1016/S0092-8674(03)00191-0	journal	March 2003
Structural Basis for the Autoinhibition of c-Abl Tyrosine Kinase Nagar, Bhushan; Hantschel, Oliver; Young, Matthew A. Cell, Vol. 112, Issue 6 https://doi.org/10.1016/S0092-8674(03)00194-6	journal	March 2003
Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer Eck, Michael J.; Yun, Cai-Hong Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics, Vol. 1804, Issue 3 https://doi.org/10.1016/j.bbapap.2009.12.010	journal	March 2010
Drug combination approach to overcome resistance to EGFR tyrosine kinase inhibitors in lung cancer Tong, Christy W. S.; Wu, William K. K.; Loong, Herbert H. F. Cancer Letters, Vol. 405 https://doi.org/10.1016/j.canlet.2017.07.023	journal	October 2017
Combining the Allosteric Inhibitor Asciminib with Ponatinib Suppresses Emergence of and Restores Efficacy against Highly Resistant BCR-ABL1 Mutants Eide, Christopher A.; Zabriskie, Matthew S.; Savage Stevens, Samantha L. Cancer Cell, Vol. 36, Issue 4 https://doi.org/10.1016/j.ccell.2019.08.004	journal	October 2019
Oncogenic Mutations Counteract Intrinsic Disorder in the EGFR Kinase and Promote Receptor Dimerization Shan, Yibing; Eastwood, Michael P.; Zhang, Xuewu Cell, Vol. 149, Issue 4 https://doi.org/10.1016/j.cell.2012.02.063	journal	May 2012
Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed Yosaatmadja, Yuliana; Silva, Shevan; Dickson, James M. Journal of Structural Biology, Vol. 192, Issue 3 https://doi.org/10.1016/j.jsb.2015.10.018	journal	December 2015
Polytherapy and Targeted Cancer Drug Resistance Chatterjee, Nilanjana; Bivona, Trever G. Trends in Cancer, Vol. 5, Issue 3 https://doi.org/10.1016/j.trecan.2019.02.003	journal	March 2019
Insight into the Therapeutic Selectivity of the Irreversible EGFR Tyrosine Kinase Inhibitor Osimertinib through Enzyme Kinetic Studies Zhai, Xiang; Ward, Richard A.; Doig, Peter Biochemistry, Vol. 59, Issue 14 https://doi.org/10.1021/acs.biochem.0c00104	journal	March 2020
Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1 Schoepfer, Joseph; Jahnke, Wolfgang; Berellini, Giuliano Journal of Medicinal Chemistry, Vol. 61, Issue 18 https://doi.org/10.1021/acs.jmedchem.8b01040	journal	August 2018
Start Selective and Rigidify: The Discovery Path toward a Next Generation of EGFR Tyrosine Kinase Inhibitors Engelhardt, Harald; Böse, Dietrich; Petronczki, Mark Journal of Medicinal Chemistry, Vol. 62, Issue 22 https://doi.org/10.1021/acs.jmedchem.9b01169	journal	November 2019
Cooperativity Between Orthosteric Inhibitors and Allosteric Inhibitor 8-Anilino-1-Naphthalene Sulfonic Acid (ANS) in Cyclin-Dependent Kinase 2 Faber, Erik B.; Tian, Defeng; Burban, David ACS Chemical Biology, Vol. 15, Issue 7 https://doi.org/10.1021/acschembio.0c00169	journal	May 2020
Complex Crystal Structures of EGFR with Third-Generation Kinase Inhibitors and Simultaneously Bound Allosteric Ligands Niggenaber, Janina; Heyden, Leonie; Grabe, Tobias ACS Medicinal Chemistry Letters, Vol. 11, Issue 12 https://doi.org/10.1021/acsmedchemlett.0c00472	journal	November 2020
Discovery and Optimization of Dibenzodiazepinones as Allosteric Mutant-Selective EGFR Inhibitors De Clercq, Dries J. H.; Heppner, David E.; To, Ciric ACS Medicinal Chemistry Letters, Vol. 10, Issue 11 https://doi.org/10.1021/acsmedchemlett.9b00381	journal	October 2019
Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor Finlay, M. Raymond V.; Anderton, Mark; Ashton, Susan Journal of Medicinal Chemistry, Vol. 57, Issue 20 https://doi.org/10.1021/jm500973a	journal	October 2014
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M Zhou, Wenjun; Ercan, Dalia; Chen, Liang Nature, Vol. 462, Issue 7276 https://doi.org/10.1038/nature08622	journal	December 2009
Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors Zhang, Jianming; Adrián, Francisco J.; Jahnke, Wolfgang Nature, Vol. 463, Issue 7280 https://doi.org/10.1038/nature08675	journal	January 2010
Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors Jia, Yong; Yun, Cai-Hong; Park, Eunyoung Nature, Vol. 534, Issue 7605 https://doi.org/10.1038/nature17960	journal	May 2016
The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1 Wylie, Andrew A.; Schoepfer, Joseph; Jahnke, Wolfgang Nature, Vol. 543, Issue 7647 https://doi.org/10.1038/nature21702	journal	March 2017
Mechanisms of cutaneous toxicities to EGFR inhibitors Lacouture, Mario E. Nature Reviews Cancer, Vol. 6, Issue 10 https://doi.org/10.1038/nrc1970	journal	October 2006
Mechanistic insights into the activation of oncogenic forms of EGF receptor Wang, Zhihong; Longo, Patti A.; Tarrant, Mary Katherine Nature Structural & Molecular Biology, Vol. 18, Issue 12 https://doi.org/10.1038/nsmb.2168	journal	November 2011
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models Li, D.; Ambrogio, L.; Shimamura, T. Oncogene, Vol. 27, Issue 34 https://doi.org/10.1038/onc.2008.109	journal	April 2008
The next tier of EGFR resistance mutations in lung cancer Tumbrink, Hannah L.; Heimsoeth, Alena; Sos, Martin L. Oncogene, Vol. 40, Issue 1 https://doi.org/10.1038/s41388-020-01510-w	journal	October 2020
An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer To, Ciric; Beyett, Tyler S.; Jang, Jaebong Nature Cancer, Vol. 3, Issue 4 https://doi.org/10.1038/s43018-022-00351-8	journal	April 2022
Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer Soria, Jean-Charles; Ohe, Yuichiro; Vansteenkiste, Johan New England Journal of Medicine, Vol. 378, Issue 2 https://doi.org/10.1056/NEJMoa1713137	journal	January 2018
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP Yun, C. -H.; Mengwasser, K. E.; Toms, A. V. Proceedings of the National Academy of Sciences, Vol. 105, Issue 6 https://doi.org/10.1073/pnas.0709662105	journal	January 2008
xia2 : an expert system for macromolecular crystallography data reduction Winter, G. Journal of Applied Crystallography, Vol. 43, Issue 1 https://doi.org/10.1107/S0021889809045701	journal	December 2009
electronic Ligand Builder and Optimization Workbench ( eLBOW ): a tool for ligand coordinate and restraint generation Moriarty, Nigel W.; Grosse-Kunstleve, Ralf W.; Adams, Paul D. Acta Crystallographica Section D Biological Crystallography, Vol. 65, Issue 10 https://doi.org/10.1107/S0907444909029436	journal	September 2009
XDS Kabsch, Wolfgang Acta Crystallographica Section D Biological Crystallography, Vol. 66, Issue 2 https://doi.org/10.1107/S0907444909047337	journal	January 2010
PHENIX: a comprehensive Python-based system for macromolecular structure solution Adams, Paul D.; Afonine, Pavel V.; Bunkóczi, Gábor Acta Crystallographica Section D Biological Crystallography, Vol. 66, Issue 2, p. 213-221 https://doi.org/10.1107/S0907444909052925	journal	January 2010
Features and development of Coot Emsley, P.; Lohkamp, B.; Scott, W. G. Acta Crystallographica Section D Biological Crystallography, Vol. 66, Issue 4 https://doi.org/10.1107/S0907444910007493	journal	March 2010
Overview of the CCP 4 suite and current developments Winn, Martyn D.; Ballard, Charles C.; Cowtan, Kevin D. Acta Crystallographica Section D Biological Crystallography, Vol. 67, Issue 4 https://doi.org/10.1107/S0907444910045749	journal	March 2011
DIALS : implementation and evaluation of a new integration package Winter, Graeme; Waterman, David G.; Parkhurst, James M. Acta Crystallographica Section D Structural Biology, Vol. 74, Issue 2 https://doi.org/10.1107/S2059798317017235	journal	February 2018
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy Paez, J. G. Science, Vol. 304, Issue 5676 https://doi.org/10.1126/science.1099314	journal	June 2004
Gefitinib Induces Apoptosis in the EGFR ^L858R Non–Small-Cell Lung Cancer Cell Line H3255 Tracy, Sean; Mukohara, Toru; Hansen, Mark Cancer Research, Vol. 64, Issue 20 https://doi.org/10.1158/0008-5472.CAN-04-1905	journal	October 2004
On-target Resistance to the Mutant-Selective EGFR Inhibitor Osimertinib Can Develop in an Allele-Specific Manner Dependent on the Original EGFR-Activating Mutation Brown, Benjamin P.; Zhang, Yun-Kai; Westover, David Clinical Cancer Research, Vol. 25, Issue 11 https://doi.org/10.1158/1078-0432.CCR-18-3829	journal	February 2019
AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer Cross, Darren A. E.; Ashton, Susan E.; Ghiorghiu, Serban Cancer Discovery, Vol. 4, Issue 9 https://doi.org/10.1158/2159-8290.CD-14-0337	journal	June 2014
Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor To, Ciric; Jang, Jaebong; Chen, Ting Cancer Discovery, Vol. 9, Issue 7 https://doi.org/10.1158/2159-8290.CD-18-0903	journal	May 2019
Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer Engelman, J. A.; Mukohara, T.; Zejnullahu, K. Journal of Clinical Investigation, Vol. 116, Issue 10 https://doi.org/10.1172/JCI28656	journal	October 2006
Phase I Trial of the Irreversible EGFR and HER2 Kinase Inhibitor BIBW 2992 in Patients With Advanced Solid Tumors Yap, Timothy A.; Vidal, Laura; Adam, Jan Journal of Clinical Oncology, Vol. 28, Issue 25 https://doi.org/10.1200/JCO.2009.26.7278	journal	September 2010
Exact Analysis of Heterotropic Interactions in Proteins: Characterization of Cooperative Ligand Binding by Isothermal Titration Calorimetry Velazquez-Campoy, Adrian; Goñi, Guillermina; Peregrina, Jose Ramon Biophysical Journal, Vol. 91, Issue 5 https://doi.org/10.1529/biophysj.106.086561	journal	September 2006
Combination therapy in combating cancer Mokhtari, Reza Bayat; Homayouni, Tina S.; Baluch, Narges Oncotarget, Vol. 8, Issue 23 https://doi.org/10.18632/oncotarget.16723	journal	March 2017
Determining EGFR-TKI sensitivity of G719X and other uncommon EGFR mutations in non-small cell lung cancer: Perplexity and solution Li, Kaidi; Yang, Maojun; Liang, Naixin Oncology Reports, Vol. 37, Issue 3 https://doi.org/10.3892/or.2017.5409	journal	January 2017

Similar Records

Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor

Journal Article · 2019 · Cancer Discovery · OSTI ID:1569902

To, Ciric; Jang, Jaebong; Chen, Ting; +15 more

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

Journal Article · 2008 · Proc. Natl. Acad. Sci. USA · OSTI ID:1006519

Yun, C H; Mengwasser, K E; Toms, A V; +5 more

Targeting ROR1 in combination with osimertinib in EGFR mutant lung cancer cells

Journal Article · 2021 · Experimental Cell Research · OSTI ID:23195272

Nakagawa, Nozomu; Miyake, Noriko; Ochi, Nobuaki; +3 more

Title: Molecular basis for cooperative binding and synergy of ATP-site and allosteric EGFR inhibitors

Citation Formats

References (46)

Similar Records

Related Subjects